In addition, studies utilising the irreversible PPARγ-selective antagonist GW9662, have revealed PPARγ-dependent and -independent mechanisms of growth inhibition [21,24-26], further highlighting the incongruity of responsiveness between cancer types. The gene discussed is PPARG; the disease is cancer.